ProCE Banner Activity

Clinical Activity and Safety of IDH2 Inhibitor Enasidenib (AG-221) in IDH2-Mutant Relapsed/Refractory AML

Slideset Download
Conference Coverage
Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Released: June 12, 2017

Expiration: June 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology